Neurocrine Biosciences sold $53 million of CRENESSITY in the second quarter of 2025. A year later, the same drug brought in $184 million, and a second rare-disease product, acquired in May, added $54 million in…
Recovering from addiction often involves more than stopping substance use. It requires understanding personal triggers, developing healthier coping strategies, and learning how to manage everyday challenges without returning to harmful patterns. Intensive outpatient treatment offers…
TB-500 run as a standalone compound produces documented recovery effects in animal models covering wound healing, soft tissue regeneration, cardiac tissue repair across multiple independent research groups, giving it a preclinical foundation that exists entirely…
